Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc in January 2023. Tempus AI, Inc was incorporated in 2015 and is headquartered in Chicago, Illinois.
The Stock Analysis section offers a comprehensive ranking-based analysis alongside its peer stocks, aiding in the identification of potential future growth for the stock.
In the Technical Analysis section for this stock, various timeframes, moving averages, and technical indicators offer insights into sentiment trends, helping forecast whether the prevailing sentiment suggests a buy or sell recommendation.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Tempus AI conducted its IPO last week. The healthcare AI company has financial backing from Google....
Nothing is hotter in tech right now than artificial intelligence. No wonder then that many AI companies see 2024 as the year to go public....
One large IPO priced this past week, while the other scheduled deal was pulled. Two blank checks also began trading - Tempus AI, Telix Pharmaceuticals, Centurion Acquisition, and Perceptive Capital So...
Tempus AI, Inc, aims to revolutionize precision medicine with AI technology and healthcare data. The promise looks good, as the revenue base is substantial, but unfortunately the same applies to the l...
Shares of healthcare technology firm Tempus AI surged Friday as they began trading on the Nasdaq....
SoftBank Group-backed Tempus AI shares surged over 15% after its Nasdaq debut Friday, valuing the AI-driven genetic testing company at around $6.6 billion. The stock opened at $40 per share and rose t...
Shares of SoftBank Group-backed Tempus AI rose 8.1% in their debut on the Nasdaq on Friday, giving the artificial intelligence-based genetic testing company a valuation of $6.6 billion....
One of the season's most highly anticipated initial public offerings (IPOs) is taking place today. Tempus AI (NASDAQ: TEM ), a company bringing artificial intelligence (AI) to the data processing spac...
Tempus AI founder and CEO Eric Lefkofsky joins 'Squawk Box' to discuss taking the company public on Nasdaq later today, the origin of the company,...
SoftBank Group-backed Tempus AI announced on Thursday the pricing of its initial public offering of 11.1 million ordinary shares at a price of $37 apiece....
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) today announced the pricing of its initial public offering of 11,100,000 shares of its Class A common stock at a public offering price of $37.0...
Tempus AI stock is preparing for an initial public offering ( IPO ) and we have all of the details that traders need to know about before it gets here. Let's get into all of the latest Tempus AI IPO d...
Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.